Literature DB >> 15375544

Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.

Qimin He1, Yongrong Mao, Jainping Wu, Catrine Decker, Malik Merza, Naining Wang, Staffan Eriksson, Juan Castro, Sven Skog.   

Abstract

Thymidine kinase 1 (TK1), an enzyme involved in the synthesis of precursors for DNA, and thus proliferation dependent, has been suggested as a good tumour marker. We have recently developed poly/monoclonal antibodies against TK1, which proved useful for diagnostics in both serum and immunohistochemistry of cancer patients. The anti-TK1 monoclonal antibodies (mAbs) 1D11 and 1E3 were characterized by Western blot, immunoprecipitation and flow cytometry. TK1 mAbs and Ki-67 mAb were then used for immunohistochemistry staining of tumour sections from 54 patients with ductal infiltrated breast carcinoma. Results showed the relative number of patients with positively stained tumours for TK1 (mAb 1D11) and for Ki-67 (mAb MIB-1) were 47 and 41%, respectively, significantly related (p=0.007). Combination of TK1 mAbs 1D11 and 1E3 increased this number to 56%, due to detection of a significantly higher number of patients with grade 2 tumours. Patients with stage II and grade 2 tumours showed significantly higher TK1 staining when compared to stage I and grade 1. Ki-67 staining was significantly higher in stage III and grade 3. The tumours only stained for TK1 represented higher stages and grades, while tumours staining only for Ki-67 were of lower stages and grades. Combining TK1 and Ki-67 increased the number of patients with positively stained tumours to 69%. In conclusion, TK1 is a reliable marker for identification of patients with grade 2 tumours. The highest number of patients with positively stained tumours were obtained when both TK1 and Ki-67 markers were used.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375544

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

2.  Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.

Authors:  Zhu-Lin Pan; Xing-Ying Ji; Yan-Min Shi; Ji Zhou; Ellen He; Sven Skog
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-07       Impact factor: 4.553

3.  Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.

Authors:  Yongping Liu; Yang Ling; Qiufeng Qi; Yexin Tang; Jianzhong Xu; Zhou Tong; Guifeng Sheng; Quanliang Yang; Yaodong Pan
Journal:  Exp Ther Med       Date:  2011-08-17       Impact factor: 2.447

4.  XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.

Authors:  Stefan Aufderklamm; Jörg Hennenlotter; Tilman Todenhoefer; Georgios Gakis; David Schilling; Ulrich Vogel; Ursula Kuehs; Johannes Dlugosch; Judith Knapp; Axel Merseburger; Valentina Gerber; Anna Ordelheide; Joachim Hevler; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

5.  XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.

Authors:  Georgios Gakis; Joerg Hennenlotter; Marcus Scharpf; Joachim Hevler; David Schilling; Ursula Kuehs; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2010-11-27       Impact factor: 4.226

6.  The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells.

Authors:  Pengcheng Luo; Naining Wang; Ellen He; Staffan Eriksson; Ji Zhou; Guozhu Hu; Jie Zhang; Sven Skog
Journal:  Pathol Oncol Res       Date:  2009-12-03       Impact factor: 3.201

Review 7.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

8.  Thymidine kinase 1 upregulation is an early event in breast tumor formation.

Authors:  Melissa M Alegre; Richard A Robison; Kim L O'Neill
Journal:  J Oncol       Date:  2012-06-19       Impact factor: 4.375

9.  Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.

Authors:  Yari Ciribilli; Prashant Singh; Reinhard Spanel; Alberto Inga; Jürgen Borlak
Journal:  Oncotarget       Date:  2015-10-13

10.  Design, synthesis, and in vitro and in vivo biological studies of a 3'-deoxythymidine conjugate that potentially kills cancer cells selectively.

Authors:  Qiong Wei; Dejun Zhang; Anna Yao; Liyi Mai; Zhiwei Zhang; Qibing Zhou
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.